E3 ubiquitin-protein ligase synoviolin (SYVN1) (SYVN1)

E3 ubiquitin-protein ligase synoviolin, commonly known as SYVN1 or HRD1, is a critical enzyme localized to the endoplasmic reticulum (ER) membrane where it functions as a key component of the ER-associated degradation (ERAD) pathway [1, 5, 8]. It identifies and ubiquitinates misfolded or short-lived proteins, facilitating their retrograde transport to the cytosol for proteasomal degradation [8, 10, 13]. Synoviolin plays a vital role in maintaining cellular homeostasis by protecting cells from ER stress-induced apoptosis through the degradation of pro-apoptotic factors such as IRE1 and p53 [4, 10, 12]. In disease states, particularly rheumatoid arthritis, synoviolin is significantly overexpressed in synovial cells, leading to pathological hyperplasia and joint destruction by suppressing normal apoptotic processes [7, 16]. It also regulates energy metabolism by targeting the transcriptional coactivator PGC-1β for degradation, which links its function to the development of obesity and metabolic disorders [2, 9, 17]. Therapeutic strategies targeting synoviolin involve small molecule inhibitors, such as LS-102, which aim to restore substrate stability and induce apoptosis in hyperproliferative tissues [2, 9, 17]. However, because synoviolin is essential for embryogenesis and liver development, systemic inhibition presents significant safety challenges and therapeutic hurdles [4, 7, 10].

Other names

HRD1DER3Synoviolin 1Synovial apoptosis inhibitor 1HMG-CoA reductase degradation 1 homolog

Inhibition of E3 ubiquitin ligase activity to stabilize substrate proteins and promote apoptosis in hyperproliferative cells.